

FAX RECEIVED

MAY 24 2002

I hereby certify that this correspondence is being transmitted via facsimile to the U.S. Patent and Trademark Office in Washington, D.C. on May 23, 2002.

Frank C. Eisenschenk  
Frank C. Eisenschenk, Ph.D., Patent Attorney

COMMUNICATIONS GROUP 1600  
Examining Group 1631  
Patent Application  
Docket No. GEN-T112XC1  
Serial No. 09/326,402

OFFICIAL

#25  
BP  
5-28-02

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Mary K. Zeman  
Art Unit : 1631  
Applicants : Marta Blumenfeld, Lydie Bougueleret, Ilya Chumakov,  
Serial No. : 09/326,402  
Filed : June 4, 1999  
Confirm. No. : 4132  
For : Polymorphic Markers of Prostate Carcinoma Tumor Antigen-1  
(PCTA-1)

U. S. Patent and Trademark Office  
Washington, D.C.

COMMUNICATION

Attached hereto please find a copy of the Election filed by facsimile transmission on March 11, 2002, with copies of the facsimile transmission sheet, transaction report, and the RightFax Auto-Reply Facsimile Transmission report acknowledging receipt by the Patent Office on March 11, 2002. A telephone inquiry to the group receptionist indicates this Election has not been matched with the file at the Patent Office, and is enclosed herewith for consideration.

Respectfully submitted,

Frank C. Eisenschenk

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100


Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik  
A Professional Association  
2421 NW 41st Street, Suite A-1  
Gainesville, FL 32606-6669

FCE/jaj

Attachments: March 11, 2002 Election  
Copies of March 11, 2002 Facsimile Cover Sheet and Transaction Report  
Copy of March 11, 2002 RightFax Acknowledgement Report

I hereby certify that this correspondence is being  
facsimile transmitted to the United States Patent and  
Trademark Office on March 11, 2002.

  
Frank C. Eisenschenk, Ph.D., Patent Attorney

#25  
ELECTION  
Examining Group 1631  
Patent Application  
Docket No. GEN-T112XC1  
Serial No. 09/326,402

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Mary K. Zeman  
Art Unit : 1631  
Applicants : Marta Blumenfeld, Lydie Bougueleret, Iyla Chumakov  
Serial No. : 09/326,402  
Filed : June 4, 1999  
Conf. No. : 4132  
For : Polymorphic Markers of Prostate Carcinoma Tumor Antigen-1  
(PCTA-1)

Assistant Commissioner for Patents  
Washington, D.C. 20231

ELECTION

Sir:

In response to the restriction requirement of February 11, 2002, Applicants elect, with  
traverse, the single polymorphic site at position 402 of SEQ ID NO:12.

Remarks

Claims 121-141, 150-152, and 163-182 are pending and subject to a restriction requirement  
in this application. Therefore, claims 121-141, 150-152, and 163-182 are drawn to the elected  
invention.

Applicants respectfully traverse the restriction requirement as set forth in the Office Action of  
April 18, 2001 and request that the Examiner rejoin the inventions. It is respectfully submitted that  
rejoinder of the inventions would not create an undue search or examination burden on the Examiner  
or the Patent Office.

## FACSIMILE COVER SHEET

**SALIWANCHIK, LLOYD & SALIWANCHIK**

A Professional Association  
2421 N.W. 41st Street  
Suite A-1  
Gainesville, FL 32606

Telephone (352) 375-8100  
Facsimile (352) 372-5800

**TO:** Examiner Mary K. Zeman

**FROM:** Frank C. Eisenschenk, Ph.D.  
(Reg. No. 45,332)

**COMPANY:** U.S. Patent & Trademark Office,  
Art Unit 1631

**DATE:** March 11, 2002

**FAX NO.:** (703) 872-9306

**NO. OF PAGES:**  
(INCLUDING COVER SHEET) 4

**SUBJECT/MESSAGE:**

Re: U.S. Patent Application Docket No. GEN-T112XC1

**POLYMORPHIC MARKERS OF PROSTATE CARCINOMA TUMOR  
ANTIGEN-1 (PCTA-1)**

(Blumenfeld *et al.*)

Serial No. 09/326,402; Filed June 4, 1999

**THIS IS AN OFFICIAL DOCUMENT.  
PLEASE DELIVER IMMEDIATELY. Thank you.**

Attachment: Election

*The information contained in this facsimile message is intended only for the personal and confidential use of the designated recipients named above. This message may be an attorney-client communication, and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message by mail. Thank you.*

*If you do not receive all pages or if any transmission is not legible, call the sender at (352) 375-8100.*